Acquisition of industry-leading instrument by
Thermo Fisher Scientific will significantly advance psychedelic
research and accelerate third-party standardized testing
capabilities
VANCOUVER, BC, Jan. 13, 2021 /CNW/ - Numinus Wellness
Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company
creating an ecosystem of health solutions centered around
developing and supporting the safe, evidence-based, accessible use
of psychedelic-assisted psychotherapies (PAP), is excited to
announce it has acquired the Orbitrap Exploris 120 mass
spectrometer with Vanquish Flex Binary ("Orbitrap") instrument
for its continued research and development of Psilocybe
mushroom related projects at Numinus Bioscience, the
Company's 7,000 square foot analytics and research laboratory.
Implementation of the Orbitrap, a state-of-the-art high
resolution mass spectrometry instrument, will continue the
accelerated trajectory of Numinus Bioscience's research strategy to
optimize cultivation, harvest, and extraction of Psilocybe
mushrooms. This follows Numinus' successful completion of the first
legal extraction in Canada by a
public company for research and development purposes in
December.
"Numinus continues to break ground in the research and
development of psychedelic-assisted psychotherapies, and the
implementation of the Orbitrap Exploris 120 mass spectrometer
with Vanquish Flex Binary cements our role as the centre of
excellence for psychedelic research and development," said
Sharan Sidhu, Science Officer and
General Manager, Numinus. "As an early psychedelic substances
license holder, this announcement demonstrates our commitment to
staying at the forefront of psychedelic initiatives. Acquiring the
Orbitrap is a fundamental step forward in developing Numinus
Bioscience's first patent, significantly advancing Psilocybe
Mushroom related psychedelic discovery research and accelerating
our third-party psychedelic standardized testing capabilities."
Numinus Bioscience is focused on developing analytical methods
and formulations for the evolving psychedelics space by
establishing itself at the forefront of analytical testing for
psychedelics. Use of the Orbitrap Exploris 120 will allow Numinus
to accelerate psychedelic standardized testing, research and
development activities for third-party clients and strategic
partners, as well as high throughput testing for amenable
compounds.
As well, the Orbitrap will be instrumental in ensuring that
dried Psilocybe Mushrooms provided for special access are
safe and that the therapeutic compounds consistently meet all
required specifications. This follows Health Canada's
groundbreaking announcement of its intention to revise the Special
Access Programme (SAP) to permit access to MDMA and
psilocybin-assisted psychotherapy in the same way other
investigational medications are accessed in Canada.
Health Canada's Notice of
Intent regarding the SAP will be open for public consultation and
comments for the next 60 days, and Numinus strongly encourages the
community to weigh in on the benefits of the revision. View the
notice
here: http://www.gazette.gc.ca/rp-pr/p1/2020/2020-12-12/html/notice-avis-eng.html#nb2.
To share comments and thoughts related to the SAP, please email
hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca.
About Psychedelic-Assisted Psychotherapy
Psychedelic-assisted psychotherapy has gained a great deal of
interest within the medical community and general public
as research results demonstrate its superior effectiveness for
a range of mental health conditions. These results are contributing
to a paradigm shift in both the understanding and treatment of
mental health conditions.
Numinus has announced plans to embark upon open-label
compassionate access clinical trials of psilocybin-assisted
psychotherapy for substance use disorders and MDMA-assisted
psychotherapy for PTSD, enabling it to implement, test and refine
optimal protocols for delivery before these therapies are widely
accessible. This includes developing physical and human resource
infrastructure more broadly to deliver psychedelic-assisted
psychotherapy including for Special Access Programme patients.
Numinus is uniquely positioned to provide patients with MDMA and
psilocybin-assisted psychotherapy under the expanded SAP revision
based on its international partnerships and extensive work
completed on developing safe and evidence-based protocols for
psychedelic-assisted psychotherapy. The Company is also a leader in
the industry as the first public entity in Canada to receive a licence to produce and
extract psilocybin from mushrooms, the first to complete a legal
harvest and extraction of Psilocybe mushrooms using this
licence and the holder of a Health Canada dealer's licence to
import, export, possess, test and distribute MDMA, psilocybin and
other psychedelics.
Applications for Numinus's compassionate access trials and for
access under the SAP, pending approval, are not yet open. To be
advised of the status and procedures for applications when
available, register for Numinus's newsletter.
About Numinus
Numinus Wellness Inc. (TSXV: NUMI) is a mental
health and wellness company creating an ecosystem of solutions
centred around safe, evidence-based, accessible
psychedelic-assisted psychotherapy to help people heal and be
well.
Numinus Health is dedicated to delivering innovative
treatments to address physical, mental, and emotional health,
through clinics and virtual services.
Numinus R&D is conducting implementation science
and leveraging partnerships to beta-test and refine optimal models
of psychedelic-assisted psychotherapy delivery, setting the stage
for approved routine use in mental health and wellness care.
Numinus Bioscience is focused on developing testing
methods and effective formulas for the evolving psychedelics space.
Health Canada licences, scientific
expertise, and new technologies facilitate ongoing innovation, and
high-throughput contract services generate established revenue.
Learn more at numinus.ca, and follow us on Facebook, Twitter,
and Instagram.
Forward Looking Statements
This news release contains forward-looking statements within
the meaning of applicable securities laws. All statements that are
not historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, are "forward-looking statements."
Forward-looking statements can be identified by the use of words
such as "plans", "expects" or "does not expect", "is expected",
"estimates", "intends", "anticipates" or "does not anticipate", or
"believes", or variations of such words and phrases or statements
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward looking statements. Such risks and uncertainties include,
among others, dependence on obtaining and maintaining regulatory
approvals, including acquiring and renewing federal, provincial,
municipal, local or other licences and any inability to obtain all
necessary governmental approvals licences and permits to operate
and expand the Company's facilities; regulatory or political change
such as changes in applicable laws and regulations, including
federal and provincial legalization, due to inconsistent public
opinion, perception of the medical-use and adult-use marijuana
industry, bureaucratic delays or inefficiencies or any other
reasons; any other factors or developments which may hinder market
growth; the Company's limited operating history and lack of
historical profits; reliance on management; the Company's
requirements for additional financing, and the effect of capital
market conditions and other factors on capital availability;
competition, including from more established or better financed
competitors; and the need to secure and maintain corporate
alliances and partnerships, including with research and development
institutions, customers and suppliers. These factors should be
considered carefully, and readers are cautioned not to place undue
reliance on such forward-looking statements. Although the Company
has attempted to identify important risk factors that could cause
actual actions, events or results to differ materially from those
described in forward-looking statements, there may be other risk
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. There can be no assurance that
forward-looking statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in forward-looking statements. The Company has no
obligation to update any forward-looking statement, even if new
information becomes available as a result of future events, new
information or for any other reason except as required by
law.
SOURCE Numinus Wellness Inc.